Special Issue "Pathogenetic and Therapeutic Significance of Adipokines in Diabetes"
Deadline for manuscript submissions: closed (30 June 2019).
Associate Professor, Department of Functional Genomics, University of Science and Technology (UST), Daejeon, Korea.
Interests: Glucose/Lipid metabolism and Insulin Resistance in Type 2 DM and Obesity; Liver/Muscle Energy metabolism; Adipose tissue metabolism and Obesity & Type 2 DM
No less than 75~90% of patients with Type 2 diabetes are overweight and obese. Namely, obesity is one of the strongest risk factors for development of type 2 diabetes. Dr. Francine Kaufman coined the term “Diabesity (diabetes+obesity)” to describe it. The World Health Organization (WHO) considers both obesity and diabetes as global epidemic and pandemic diseases. Obesity is defined as a condition of excessive body fat accumulation, and excess adiposity and adipocyte dysfunction can cause whole-body insulin resistance. Adipose tissue produces and secretes adipocyte-specific autocrine, paracrine, endocrine hormones (adipokines) that allow communication amongst metabolic organs and can regulate the energy balance at the cellular and whole-body levels. Recent reports showed that obese diabetic patients exhibit the altered adipokine profile. Adipokines are characterized by both pro-inflammatory and anti-inflammatory activities. The production of pro-inflammatory adipokines, such as leptin, resistin, and tumor necrosis factor α (TNFα) is associated with the development of obesity and type 2 diabetes. Conversely, anti-inflammatory adipokines, such as adiponectin, FGF21 and SFRP5, are triggered by conditions to improve energy metabolism, such as exercise and cold-induced thermogenesis, which has been highlighted as a method for consuming energy without physical activity. Therefore, anti-inflammatory adipokines are considered as attractive therapeutic targets for the treatment of obesity and type II diabetes.
In this Special Issue, we will focus on understanding the pathological disturbed profile of adipokines in diabetes, and discuss adipokines as critical therapeutic targets for the treatment of diabetes.
Prof. Dr. Kyoung-Jin Oh
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Type 2 diabetes
- Insulin resistance
- Adipokine as an Endocrine hormone
- Communication amongst metabolic organs
- Pro-inflammatory adipokines
- Anti-inflammatory adipokines
- Disturbed adipokine profile in diabetes
- Adipokines as therapeutic targets for treatment of diabetes